Cellceutix Corporation
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cellceutix Corporation - overview
Location
Beverly Hills, CA, US
Primary Industry
Pharmaceuticals
About
Cellceutix Corporation is a biopharmaceutical company focused on developing innovative treatments for dermatology, oncology, and antibiotic applications, leveraging advanced clinical trials to address critical healthcare needs. Cellceutix Corporation specializes in creating biopharmaceutical products. Founded by Leo Ehrlich, the company is headquartered in Beverly Hills, US. In May 2012, it raised USD 1.
00 mn from unspecified investors, furthering its mission to enhance therapeutic options. The company has undergone strategic pivots to refine its product focus but has not indicated any parent or subsidiary relationships. Cellceutix develops biopharmaceutical products aimed at treating dermatology, oncology, anti-inflammatory conditions, and antibiotics. Its notable products include Prurisol, a treatment for psoriasis currently in Phase 2b trials; Kevetrin, designed to modulate the p53 gene in cancer treatment, also in Phase 2a trials; and Brilacidin, an innovative immunomodulatory drug.
The company primarily serves the US healthcare market but intends to expand internationally as its products receive regulatory approval. Cellceutix's revenue model is centered on partnerships and collaborations with healthcare providers and research institutions. Revenue is generated from the commercialization of proprietary drugs post-clinical trials and regulatory approval. Its key products—Prurisol, Kevetrin, and Brilacidin—are integral to its revenue strategy, involving agreements with pharmaceutical distribution partners and health systems to reach end-users like hospitals and dermatology clinics.
Cellceutix Corporation plans to leverage its recent financing of USD 1. 00 mn from May 2012 to support the advancement of its clinical trials and expand market presence. The company is focused on the release of Prurisol and Kevetrin as it progresses through clinical trials and aims for international market entry by capitalizing on successful regulatory approvals. Specific geographic regions targeted for expansion will be identified as the products reach commercialization milestones.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.cellceutix.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Cellceutix Corporation - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.